PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2008
CASE
AUTH/2167/9/08 Pfizer

AUTH/2167/9/08: Pfizer breached the Code over Toviaz superiority and β€œnew step” claims (Astellas complaint)

Pfizer’s Toviaz ad claimed superiority vs tolterodine based on a post hoc analysis and called Toviaz β€œa new step” in OAB. The…

2009
CASE
AUTH/2260/9/09 Boehringer Ingelheim

AUTH/2260/9/09: Boehringer Ingelheim rep emailed misleading/disparaging claims about Xarelto (rivaroxaban)

Boehringer Ingelheim admitted a rep emailed an orthopaedic surgeon claiming rivaroxaban was removed from a formulary due to bleeding concerns. PMCPA found…

2009
CASE
AUTH/2239/6/09 Bracco

Bracco letter about US court case found misleading and disparaging (AUTH/2239/6/09)

Bracco sent 3,221 UK radiology HCPs a letter summarising a US legal case vs GE Healthcare. The PMCPA ruled the summary was…

2009
CASE
AUTH/2215/3/09 Allergan

Merz v Allergan: Botox β€œ20 licensed indications worldwide” and β€œA BIG difference” claims ruled misleading (AUTH/2215/3/09)

Allergan’s Botox materials referenced β€œ20 licensed indications worldwide” and used the headline β€œA BIG difference”. PMCPA ruled the worldwide indications framing and…

AUTH/2198/10/9 Solvay ⭐ Case of the Week

AUTH/2198/10/9: Primary Care Trust v Solvay β€” Not stated

PMCPA case summary for AUTH/2198/10/9 (Primary Care Trust v Solvay). The provided case text contains no details on allegations, outcome, clauses, or…

2010
CASE
AUTH/2302/3/10 Ferring Pharmaceuticals

Ferring: β€œNPSA recommends” claim in Glypressin tender letter ruled misleading (AUTH/2302/3/10)

A β€œDear Pharmacist” tender letter claimed the NPSA β€œrecommends” only licensed ready-to-use injectables. PMCPA said the NPSA expressed a preference and the…

2018
CASE
AUTH/3053/7/18 Daiichi-Sankyo UK

Anonymous doctor v Daiichi-Sankyo: speaker expenses and family hospitality (AUTH/3053/7/18)

A UK speaker meeting complaint found Daiichi-Sankyo reimbursed a US speaker for drinks likely consumed by accompanying family members. Breach of hospitality…

2010
CASE
AUTH/2337/7/10 Sandoz

AUTH/2337/7/10: Merck Serono v Sandoz β€” Omnitrope press release and draft patient newsletter article

Sandoz’s German-issued press release referencing NICE guidance was held to be within the UK Code. One statement implying NICE found β€œno differences”…

2008
CASE
Pfizer

Allergan v Pfizer: speculative 5‑year budget model and β€˜significant savings’ patent-loss messaging for Xalatan/Xalacom

Pfizer’s 5‑year budget impact model and ad promoted Xalatan/Xalacom using speculative post‑patent savings and referenced a paediatric programme inconsistent with the SPC.…

2019
CASE
AUTH/3169/3/19 Otsuka ⭐ Case of the Week

Otsuka Europe voluntary admission: unclear SPC update communications for Jinarc and out-of-date package leaflet (AUTH/3169/3/19)

Otsuka Europe admitted potential Code issues after confusing affiliate communications on parallel Jinarc SPC variations and an out-of-date package leaflet being packed.…

2019
CASE
AUTH/3182/4/19 Astellas

Astellas breached ABPI Code after repeated calls to pharmacist who said they didn’t speak to industry (AUTH/3182/4/19)

A pharmacist complained about repeated calls from Astellas reps about formulary approval. The Panel found the pharmacist’s wishes weren’t observed (breach Clauses…

2019
CASE
AUTH/3148/1/19 GlaxoSmithKline

GSK: Seretide digital banner β€˜back-up’ frame treated as separate ad; breach for non-proprietary name not adjacent/legible (AUTH/3148/1/19)

A Seretide Evohaler digital banner in Pulse rotated across 4 frames, but a media agency set frame 2 as a static β€˜back-up’.…

2019
CASE
AUTH/3232/7/19 Boehringer Ingelheim

AUTH/3232/7/19 & AUTH/3233/7/19: Public complaint about POM congress stand visibility (No breach)

A member of the public alleged POM promotional panels at ExCeL London were visible/readable from a public coffee area. Panel found the…

2010
CASE
AUTH/2351/8/10 Roche Products

AUTH/2351/8/10: Lilly v Roche – Promotion of Tarceva and the meaning of β€œfirst-line maintenance” (No breach on appeal)

Lilly challenged Roche’s use of β€œfirst-line maintenance” for Tarceva across a leavepiece, ad and sponsored feature. Panel found breaches, but the Appeal…

2008
CASE
Sanofi ⭐ Case of the Week

Sanofi-Aventis: HSJ β€˜special report’ found to be disguised promotion for dronedarone (Clause 12.1)

A sponsored HSJ β€˜special report’ on atrial fibrillation looked like independent editorial and favoured dronedarone. PMCPA ruled Sanofi-Aventis was inextricably linked to…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training